|
Synonyms: 4-androstadienol | [3β]-androsta-4,16-dien-3-ol | aloradine | PH-94B | PH94B
Compound class:
Synthetic organic
Comment: Fasedienol (PH94B; VistaGen Therapeutics, formerly Pherin Pharmaceuticals) is a pherine, or vomeropherin [4]. Pherines are synthetic neuroactive steroids that are intended to acts as human pheromones via interactions with receptors on nasal chemosensory neurons within the vomeronasal organ (VNO). They are proposed to alter central nervous system activity (e.g., within the limbic amygdala and hypothalamus) through the olfactory system, and without crossing the blood-brain barrier, in turn inducing physiological, pharmacological and behavioural changes. Fasedienol is claimed to be pharmacologically active, achieving rapid-onset and short-duration anxiolytic effects, without systemic distribution or direct activity on neurons in the brain. Note that whilst intranasal administration of fasedienol in human subjects is reported to elicit biological and physiological responses [2-3], the functional capacity of vomeronasal receptors and the VNO in humans is open to debate [1,5-7].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Fasedienol (PH94B) was progressed as a clinical candidate, proposed to alleviate social anxiety disorder. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06809179 | A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder | Phase 2 Interventional | VistaGen Therapeutics, Inc. | ||
| NCT02622958 | Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) | Phase 3 Interventional | Pherin Pharmaceuticals, Inc. | 2 | |
| NCT06358651 | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) | Phase 3 Interventional | VistaGen Therapeutics, Inc. | The PALISADE-3 study: In December 2025 Vistagen reported that intranasal fasedienol provided no statistically better effect than placebo (measured as improvement in a self-reported distress assessment) in participants with social anxiety disorder (SAD). | |
| NCT06615557 | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) | Phase 3 Interventional | VistaGen Therapeutics, Inc. | The PALISADE-4 study: In June 2026 it was reported that compared to placebo, fasedienol did not reduce anxiety symptoms in subjects who participated in a simulated anxiety-inducing public speaking challenge [...]. A marginally statistically significant beneficial effect was noted when analysing the Subjective Units of Distress Scale (SUDS) as the primary endpoint in a subpopulation of patients with pre-existing very severe social anxiety, (n=123, out of a total of 238 trial recruitees). | |